GLP-1 therapy works best when paired with professional follow-up, individualized dosing, and a supportive healthcare team
The most remarkable clinically Important pharmacokinetic characteristic is the difference between the short-acting and continuous-acting compounds (Table 1) [13]
This assessment focused on various factors including randomized sequence generation, treatment allocation concealment, blinding, completeness of outcome data, as well as selective outcome reporting and other potential sources of bias
Posted April 21, 2025 Reviewed by Monica Vilhauer Ph.D
Mazdutide (IBI362 or LY3305677) is a once-weekly oxyntomodulin analogue which acts both on GLP-1 and glucagon receptors [65]
Lancet 394:131138 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial